Introduction
NSCLC, death, endometrial cancer, cancer, Lung cancer, mismatch repair-deficient, MSI-H, deaths
ENDOMETRIAL CANCER, CANCER, LUNG CANCER, SOLID TUMORS, NSCLC
Lung cancer is one of the most common forms of cancer globally, with an estimated 1.8 million related deaths in 2020 aloneIn recent years, outcomes for patients with NSCLC in the 1 L setting have improved with the introduction of targeted therapies for patients with oncogenic drivers, and immunotherapies for those without targetable oncogenic drivers. Immunotherapies include programmed death receptor-1/programmed death-ligand 1 (PD-[L]1) inhibitors, either as monotherapy (for patients with high levels of PD-L1 expression) or in combination with chemotherapy (irrespective of PD-L1 expression)Dostarlimab is an anti-PD-1 monoclonal antibody approved as a monotherapy in the European Union for recurrent or advanced mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer that has progressed on or after platinum-based chemotherapy and in the US for recurrent or advanced dMMR endometrial cancer that has progressed on or after platinum-based chemotherapy as well as dMMR solid tumors following prior treatment and with no alternative treatment optionsHere, we show that in the PERLA study, dostarlimab plus chemotherapy has comparable efficacy to pembrolizumab plus chemotherapy as 1 L treatment for patients with metastatic non-squamous NSCLC without targetable oncogenic driver mutations. Safety profiles are also comparable and consistent with published data in PD-(L)1 inhibitors.